Article

Study: PDS offers efficient drug delivery to retina for wet AMD

Author(s):

Mark Wieland, MD, explores how Port Delivery System with ranibizumab provides drug delivery over an extended period.

Study: PDS offers efficient drug delivery to retina for wet AMD

The Port Delivery System with ranibizumab (Susvimo, Roche/Genentech), an ocular implant approved recently to treat wet age-related macular degeneration (AMD), provides drug delivery over an extended period.

The implant provides a dose of 100 mg/ml that is released over 6 months. The implant was approved based on the results of the Archway phase 3 study in which the results of the implant were compared with the results achieved with injections of ranibizumab alone.

Retina specialists Mark Wieland, MD, and Jay Stewart, MD, looked at the implant’s release and refill-exchange efficiency in vitro and reported that “about 70% of the ranibizumab 100 mg/mL was released from the implant over 6 months; levels were unmeasurable after 450 days.”

Weiland discussed their findings during a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans.

Specifically, the mean respective active release rates at 6 months, expressed as µg/day, were 3.95, 3.99, 3.85, and 4.00 at the initial filling of the implant and at the first, second, and third refill/exchanges, they reported.

They also found that during refilling of the implant, about 98% of the previous implant contents were replaced with fresh drug in one 100 mg/mL refill.

The investigators concluded that the PDS continuously and reproducibly delivers ranibizumab over a period of months while maintaining its potency.

See more AAO meeting coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.